Indegene Limited has informed the Exchange about Acquisition
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indegene Limited's wholly owned subsidiaries — Indegene Inc. (USA) and Trilogy Writing and Consulting GmbH — have signed a Share Purchase Agreement to acquire 100% equity in Trilogy Writing & Consulting Inc. (Canada), a medical writing firm in the healthcare space. The deal is being done as an internal restructuring, with cash consideration of EUR 329,014, and is classified as a related party transaction carried out at arm's length. The target reported turnover of CAD 892,361 in FY2024, up from CAD 505,628 in FY2023 and CAD 369,636 in FY2022, showing strong recent growth. No regulatory approvals are required, and the acquisition is slated to complete on 31 December 2025.
This is a small, low-cost internal restructuring rather than a transformative deal, so the financial impact on Indegene is limited. However, it consolidates the medical writing business under Indegene's US subsidiary, which could support operational synergies in its healthcare-focused offerings.